RAVEN BIOTECHNOLOGIES
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
RAVEN BIOTECHNOLOGIES
Industry:
Biotechnology Medical Therapeutics
Founded:
1999-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.macrogenics.com
Total Employee:
51+
Status:
Active
Total Funding:
88.3 M USD
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amivas
Amivas is an Australian, Canadian and US joint venture that focuses on the development of therapeutics for the treatment of diseases.
Boston Biomedical
Boston Biomedical focuses on the research and development of novel therapeutics to treat cancer.
Planet Biotechnology
Planet Biotechnology is a clinical-stage company that develops monoclonal antibody-based therapeutic and preventative products.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Staten Biotechnology
Staten Biotechnology is a developer of a human monoclonal antibody intended to treat dyslipidemia.
Xori Corporation
XORI Corporation develops technology for discovery and development of monoclonal antibodies which are used to treat cancers, immune
Current Advisors List
Founder
Investors List
Biogen Idec
Biogen Idec investment in Series D - Raven Biotechnologies
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series D - Raven Biotechnologies
Hambrecht & Quist Capital Management
Hambrecht & Quist Capital Management investment in Series D - Raven Biotechnologies
CIDC Consultants
CIDC Consultants investment in Series D - Raven Biotechnologies
Milepost Ventures
Milepost Ventures investment in Series D - Raven Biotechnologies
CMEA Capital
CMEA Capital investment in Series D - Raven Biotechnologies
Bear Stearns
Bear Stearns investment in Series D - Raven Biotechnologies
Integra Ventures
Integra Ventures investment in Series D - Raven Biotechnologies
Vulcan Capital
Vulcan Capital investment in Series D - Raven Biotechnologies
U.S. Venture Partners
U.S. Venture Partners investment in Series D - Raven Biotechnologies
Official Site Inspections
http://www.macrogenics.com
- Host name: 77.113.185.35.bc.googleusercontent.com
- IP address: 35.185.113.77
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Raven Biotechnologies"
About Us - MacroGenics
MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of …See details»
Company Overview - MacroGenics
As a biopharmaceutical company, our team of 240+ dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics for the treatment of …See details»
MacroGenics, Inc. - LinkedIn
MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees can see firsthand how they contribute to the success of the …See details»
MacroGenics - Crunchbase Company Profile & Funding
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious …See details»
MacroGenics Provides Update on Corporate Progress and 2024 …
4 days ago ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, …See details»
MacroGenics - The Org
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as …See details»
SEC Filings | MacroGenics, Inc.
The Investor Relations website contains information about MacroGenics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
MacroGenics, Inc. (MGNX) Company Profile & Facts - Yahoo Finance
See the company profile for MacroGenics, Inc. (MGNX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
MacroGenics - 2025 Company Profile, Funding & Competitors
Mar 6, 2025 MacroGenics. has raised a total funding of $126M over 7 rounds. Its first funding round was on Sep 25, 2001. What are the most recent funding rounds of MacroGenics? Its …See details»
Join Our Team – MacroGenics
Employees in every department can see firsthand how they contribute to the success of the organization. ... If you are an AGENCY or a SEARCH FIRM looking to partner with …See details»
MacroGenics, Inc. Information - RocketReach
MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is …See details»
MacroGenics - Contacts, Employees, Board Members, Advisors
MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases. ... Experience the new Crunchbase, powered by AI …See details»
MacroGenics Company Profile - Office Locations, Competitors
Oct 29, 2024 MacroGenics has 4 employees across 3 locations and $58.75 m in annual revenue in FY 2023. See insights on MacroGenics including office locations, competitors, revenue, …See details»
MacroGenics Provides Update on Corporate Progress and
4 days ago MACROGENICS, INC. SELECTED CONSOLIDATED BALANCE SHEET DATA (Amounts in thousands) December 31, 2024 December 31, 2023 Cash, cash equivalents and …See details»
MacroGenics Inc Company Profile - GlobalData
MacroGenics Inc (MacroGenics) is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, …See details»
MacroGenics - Overview, News & Similar companies - ZoomInfo
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. …See details»
Our Living Values - MacroGenics
The following list of our living values reflects what is most important to us as an organization and drives all that we do. We are unwavering in our commitment to these values, which represent …See details»
MacroGenics to Participate in Upcoming Investor Conferences
Feb 27, 2025 MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody …See details»
MacroGenics, Inc. hiring Cell Line Development Intern in ... - LinkedIn
Mar 15, 2025 MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees can see firsthand how they contribute to the …See details»
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to …
3 days ago MacroGenics (MGNX) reported $19.35 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 80.5%. EPS of -$0.25 for the same …See details»